Please assess the completion status of the following clinical trial:

Trial Title: A Study With GB004 in Adult Subjects With Active Ulcerative Colitis (UC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Adult male and female subjects aged ≥ 18 years at the time of signing the informed consent form (ICF) prior to initiation of any study specific activities/procedures.~* UC diagnosed at least 3 months prior to first dose of investigational product (IP) on Day 1.~* Currently receiving treatment for UC, on a stable dose for at least 2 weeks prior to flexible sigmoidoscopy or colonoscopy, with oral 5-ASA (eg, mesalamine, sulfasalazine) alone or with one of the following oral treatments:~  1. prednisone ≤ 20 mg/day or equivalent or~ 2. beclomethasone ≤ 5 mg/day or~ 3. budesonide or budesonide multi-matrix (MMX) of ≤ 9 mg/day~Exclusion Criteria:~* Prior approved biologic therapy used for the treatment of UC.~* Diagnosis of Crohn's disease, indeterminate colitis, or pouchitis, or presence of bacterial or parasitic infection.~* Tofacitinib, oral cyclosporine, sirolimus or mycophenolate mofetil within 8 weeks of Day 1.~* Azathioprine, or 6-mercaptopurine within 1 day of Day 1.~NOTE: Other Inclusion/Exclusion criteria may apply per protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- PCP Placebo (Type: PLACEBO_COMPARATOR): PCP Placebo for oral administration for 36 weeks
- PCP GB004 480 mg QD (Type: EXPERIMENTAL): PCP GB004 480 mg QD for oral administration for 36 weeks
- PCP GB004 480 mg BID (Type: EXPERIMENTAL): PCP GB004 480 mg BID for oral administration for 36 weeks
- Open-Label Extension (OLE) GB004 480 mg BID (Type: EXPERIMENTAL): OLE GB004 480 mg BID for oral administration for 24 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).